U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory WHO Grade 3 Glioma

MedGen UID:
1659708
•Concept ID:
C4727432
•
Neoplastic Process
Synonym: Refractory WHO Grade III Glioma

Definition

A WHO grade 3 glioma that is resistant to treatment. [from NCI]

Recent clinical studies

Etiology

Survival outcome and predictors of WHO grade 2 and 3 insular gliomas: A classification based on the tumor spread.
Xue B, Hou Z, Deng Z, Sun S, Zhang C, Pan Y, Zhang Y, Li Z, Xie J
Cancer Med 2024 Jun;13(11):e7377. doi: 10.1002/cam4.7377. PMID: 38850123Free PMC Article
A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas.
Dixit KS, Sachdev S, Amidei C, Kumthekar P, Kruser TJ, Gondi V, Grimm S, Lukas RV, Nicholas MK, Chmura SJ, Fought AJ, Mehta M, Raizer JJ
J Neurooncol 2021 Dec;155(3):297-306. Epub 2021 Oct 24 doi: 10.1007/s11060-021-03875-8. PMID: 34689306
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M
Lancet Oncol 2019 Jul;20(7):1011-1022. Epub 2019 May 28 doi: 10.1016/S1470-2045(19)30277-3. PMID: 31151904Free PMC Article
Trametinib for progressive pediatric low-grade gliomas.
Kondyli M, Larouche V, Saint-Martin C, Ellezam B, Pouliot L, Sinnett D, Legault G, Crevier L, Weil A, Farmer JP, Jabado N, Perreault S
J Neurooncol 2018 Nov;140(2):435-444. Epub 2018 Aug 10 doi: 10.1007/s11060-018-2971-9. PMID: 30097824
Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma.
Geoerger B, Kieran MW, Grupp S, Perek D, Clancy J, Krygowski M, Ananthakrishnan R, Boni JP, Berkenblit A, Spunt SL
Eur J Cancer 2012 Jan;48(2):253-62. Epub 2011 Oct 25 doi: 10.1016/j.ejca.2011.09.021. PMID: 22033322Free PMC Article

Diagnosis

Survival outcome and predictors of WHO grade 2 and 3 insular gliomas: A classification based on the tumor spread.
Xue B, Hou Z, Deng Z, Sun S, Zhang C, Pan Y, Zhang Y, Li Z, Xie J
Cancer Med 2024 Jun;13(11):e7377. doi: 10.1002/cam4.7377. PMID: 38850123Free PMC Article
Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial.
Peyrl A, Chocholous M, Sabel M, Lassaletta A, Sterba J, Leblond P, Nysom K, Torsvik I, Chi SN, Perwein T, Jones N, Holm S, Nyman P, Mörse H, Öberg A, Weiler-Wichtl L, Leiss U, Haberler C, Schmook MT, Mayr L, Dieckmann K, Kool M, Gojo J, Azizi AA, André N, Kieran M, Slavc I
JAMA Oncol 2023 Dec 1;9(12):1688-1695. doi: 10.1001/jamaoncol.2023.4437. PMID: 37883081Free PMC Article
Exploration of the prognostic value of the resection of adult brainstem high-grade glioma based on competing risk model, propensity score matching, and conditional survival rate.
Zhang D, Li H, Jia W
Neurol Sci 2023 May;44(5):1755-1764. Epub 2023 Jan 6 doi: 10.1007/s10072-022-06557-z. PMID: 36604383Free PMC Article
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M
Lancet Oncol 2019 Jul;20(7):1011-1022. Epub 2019 May 28 doi: 10.1016/S1470-2045(19)30277-3. PMID: 31151904Free PMC Article
Trametinib for progressive pediatric low-grade gliomas.
Kondyli M, Larouche V, Saint-Martin C, Ellezam B, Pouliot L, Sinnett D, Legault G, Crevier L, Weil A, Farmer JP, Jabado N, Perreault S
J Neurooncol 2018 Nov;140(2):435-444. Epub 2018 Aug 10 doi: 10.1007/s11060-018-2971-9. PMID: 30097824

Therapy

Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial.
Peyrl A, Chocholous M, Sabel M, Lassaletta A, Sterba J, Leblond P, Nysom K, Torsvik I, Chi SN, Perwein T, Jones N, Holm S, Nyman P, Mörse H, Öberg A, Weiler-Wichtl L, Leiss U, Haberler C, Schmook MT, Mayr L, Dieckmann K, Kool M, Gojo J, Azizi AA, André N, Kieran M, Slavc I
JAMA Oncol 2023 Dec 1;9(12):1688-1695. doi: 10.1001/jamaoncol.2023.4437. PMID: 37883081Free PMC Article
Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.
Myers RM, Taraseviciute A, Steinberg SM, Lamble AJ, Sheppard J, Yates B, Kovach AE, Wood B, Borowitz MJ, Stetler-Stevenson M, Yuan CM, Pillai V, Foley T, Chung P, Chen L, Lee DW, Annesley C, DiNofia A, Grupp SA, John S, Bhojwani D, Brown PA, Laetsch TW, Gore L, Gardner RA, Rheingold SR, Pulsipher MA, Shah NN
J Clin Oncol 2022 Mar 20;40(9):932-944. Epub 2021 Nov 12 doi: 10.1200/JCO.21.01405. PMID: 34767461Free PMC Article
Intraarterial delivery of bevacizumab and cetuximab utilizing blood-brain barrier disruption in children with high-grade glioma and diffuse intrinsic pontine glioma: results of a phase I trial.
McCrea HJ, Ivanidze J, O'Connor A, Hersh EH, Boockvar JA, Gobin YP, Knopman J, Greenfield JP
J Neurosurg Pediatr 2021 Oct 1;28(4):371-379. Epub 2021 Aug 6 doi: 10.3171/2021.3.PEDS20738. PMID: 34359048
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M
Lancet Oncol 2019 Jul;20(7):1011-1022. Epub 2019 May 28 doi: 10.1016/S1470-2045(19)30277-3. PMID: 31151904Free PMC Article
Bevacizumab and other novel therapies for recurrent oligodendroglial tumors.
Grimm SA, Chamberlain MC
CNS Oncol 2015;4(5):333-9. Epub 2015 Oct 28 doi: 10.2217/cns.15.27. PMID: 26509217Free PMC Article

Prognosis

Survival outcome and predictors of WHO grade 2 and 3 insular gliomas: A classification based on the tumor spread.
Xue B, Hou Z, Deng Z, Sun S, Zhang C, Pan Y, Zhang Y, Li Z, Xie J
Cancer Med 2024 Jun;13(11):e7377. doi: 10.1002/cam4.7377. PMID: 38850123Free PMC Article
Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial.
Peyrl A, Chocholous M, Sabel M, Lassaletta A, Sterba J, Leblond P, Nysom K, Torsvik I, Chi SN, Perwein T, Jones N, Holm S, Nyman P, Mörse H, Öberg A, Weiler-Wichtl L, Leiss U, Haberler C, Schmook MT, Mayr L, Dieckmann K, Kool M, Gojo J, Azizi AA, André N, Kieran M, Slavc I
JAMA Oncol 2023 Dec 1;9(12):1688-1695. doi: 10.1001/jamaoncol.2023.4437. PMID: 37883081Free PMC Article
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M
Lancet Oncol 2019 Jul;20(7):1011-1022. Epub 2019 May 28 doi: 10.1016/S1470-2045(19)30277-3. PMID: 31151904Free PMC Article
Phase I study of non-pegylated liposomal doxorubicin in children with recurrent/refractory high-grade glioma.
Chastagner P, Devictor B, Geoerger B, Aerts I, Leblond P, Frappaz D, Gentet JC, Bracard S, André N
Cancer Chemother Pharmacol 2015 Aug;76(2):425-32. Epub 2015 Jun 27 doi: 10.1007/s00280-015-2781-0. PMID: 26115930
Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma.
Bouffet E, Jakacki R, Goldman S, Hargrave D, Hawkins C, Shroff M, Hukin J, Bartels U, Foreman N, Kellie S, Hilden J, Etzl M, Wilson B, Stephens D, Tabori U, Baruchel S
J Clin Oncol 2012 Apr 20;30(12):1358-63. Epub 2012 Mar 5 doi: 10.1200/JCO.2011.34.5843. PMID: 22393086

Clinical prediction guides

Survival outcome and predictors of WHO grade 2 and 3 insular gliomas: A classification based on the tumor spread.
Xue B, Hou Z, Deng Z, Sun S, Zhang C, Pan Y, Zhang Y, Li Z, Xie J
Cancer Med 2024 Jun;13(11):e7377. doi: 10.1002/cam4.7377. PMID: 38850123Free PMC Article
A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas.
Dixit KS, Sachdev S, Amidei C, Kumthekar P, Kruser TJ, Gondi V, Grimm S, Lukas RV, Nicholas MK, Chmura SJ, Fought AJ, Mehta M, Raizer JJ
J Neurooncol 2021 Dec;155(3):297-306. Epub 2021 Oct 24 doi: 10.1007/s11060-021-03875-8. PMID: 34689306
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M
Lancet Oncol 2019 Jul;20(7):1011-1022. Epub 2019 May 28 doi: 10.1016/S1470-2045(19)30277-3. PMID: 31151904Free PMC Article
Trametinib for progressive pediatric low-grade gliomas.
Kondyli M, Larouche V, Saint-Martin C, Ellezam B, Pouliot L, Sinnett D, Legault G, Crevier L, Weil A, Farmer JP, Jabado N, Perreault S
J Neurooncol 2018 Nov;140(2):435-444. Epub 2018 Aug 10 doi: 10.1007/s11060-018-2971-9. PMID: 30097824
Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma.
Geoerger B, Kieran MW, Grupp S, Perek D, Clancy J, Krygowski M, Ananthakrishnan R, Boni JP, Berkenblit A, Spunt SL
Eur J Cancer 2012 Jan;48(2):253-62. Epub 2011 Oct 25 doi: 10.1016/j.ejca.2011.09.021. PMID: 22033322Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...